Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Frank on the Initial Efficacy and Safety of CAR22 in Relapsed/Refractory LBCL

June 21st 2023

Matthew Frank, MD, PhD, discusses preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.

FDA Grants Full Approval to Blinatumomab for MRD+ B-cell Precursor ALL

June 21st 2023

The FDA has granted regular approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease of at least 0.1%

Favezelimab Plus Pembrolizumab Continues to Elicit Antitumor Activity in R/R Classical Hodgkin Lymphoma

June 21st 2023

The combination of favezelimab and pembrolizumab continued to demonstrate a manageable safety profile and antitumor activity in patients with relapsed/refractory classical Hodgkin lymphoma, irrespective of whether they received prior anti–PD-1 therapy.

FDA Approval Sought for Imetelstat for Transfusion-Dependent Anemia in Select MDS

June 21st 2023

A new drug application seeking the approval of imetelstat for use as a therapeutic option for transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndrome who have not responded to, lost response to, or were not candidates for erythropoiesis-stimulating agents has been submitted to the FDA.

Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial

June 20th 2023

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).

Dr Svoboda on the Implications of Nivolumab Plus AVD in Classical Hodgkin Lymphoma

June 19th 2023

Jakub Svoboda, MD, discusses the implications of the phase 3 SWOG 1826 trial of nivolumab plus doxorubicin, vinblastine, and dacarbazine in patients with advanced classical Hodgkin lymphoma.

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated Follicular Lymphoma, MZL

June 19th 2023

The addition of ibrutinib to bendamustine plus rituximab or R-CHOP did not lead to a statistically significant improvement in progression-free survival vs either chemoimmunotherapy regimen alone in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

Overview of Relapsed/Refractory DLBCL and Management Strategies

June 19th 2023

Key opinion leaders share a broad perspective on relapsed/refractory diffuse large B-cell lymphoma and the current treatment landscape.

Diagnosis and Frontline Management of Diffuse Large B-Cell Lymphoma

June 19th 2023

Expert panelists open their discussion on diffuse large B-cell lymphoma by reflecting on diagnostic strategies and the frontline treatment armamentarium.

Obe-Cel Demonstrates Durable, Safe Responses in Relapsed/Refractory B-ALL

June 18th 2023

Claire Roddie, MD, discusses the rationale for investigating obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population.

Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

June 16th 2023

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma

June 15th 2023

Treatment with duvelisib led to a high response rate in patients with peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma.

Importance of Early Diagnosis of MDS for Lower and Higher-risk Patients

June 15th 2023

Hetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.

Risk Stratification of Myelodysplastic Syndromes [MDS]

June 15th 2023

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

Dr Roloff on the Real-World Outcomes of Brexu-Cel in Relapsed/Refractory B-ALL

June 14th 2023

Gregory W. Roloff, MD, discusses real-world outcomes from treatment with brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia Intensiva

June 14th 2023

Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Phase 1 Trial of SC-DARIC33 in Pediatric R/R CD33+ AML on Hold After Serious Grade 5 AE

June 14th 2023

The phase 1 PLAT-08 trial investigating SC-DARIC33 in pediatric and young-adult patients with relapsed/refractory CD33-positive acute myeloid leukemia has been paused following the report of a grade 5 serious adverse effect.

Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

June 14th 2023

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

El Rol de Los Tripletes en el Tratamiento de la Leucemia Aguda Mieloblástica

June 13th 2023

Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Brentuximab Vedotin Plus Nivolumab/Chemo Elicits 98% ORR in Early-Stage Classical Hodgkin Lymphoma

June 13th 2023

Frontline treatment with the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine led to an overall response rate of 98% and a complete response rate of 93% in patients with early-stage, classical Hodgkin lymphoma.